[1] Neumann FJ, Sousa-Uva M, Ahlsson A, et al.  2018 ESC/EACTS Guidelines on myocardial revascularization[J]. Eur Heart J, 2019, 40(2): 87-165.   doi: 10.1093/eurheartj/ehy394
[2] Knuuti J, Wijns W, Saraste A, et al.  2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: the task force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC)[J]. Eur Heart J, 2020, 41(3): 407-477.   doi: 10.1093/eurheartj/ehz425
[3] Garcia MJ, Kwong RY, Scherrer-Crosbie M, et al.  State of the art: imaging for myocardial viability: a scientific statement from the American heart association[J]. Circ Cardiovasc Imaging, 2020, 13(7): e000053-.   doi: 10.1161/hci.0000000000000053
[4] Rischpler C, Langwieser N, Souvatzoglou M, et al.  PET/MRI early after myocardial infarction: evaluation of viability with late gadolinium enhancement transmurality vs. 18F-FDG uptake[J]. Eur Heart J Cardiovasc Imaging, 2015, 16(6): 661-669.   doi: 10.1093/ehjci/jeu317
[5] Vitadello T, Kunze KP, Nekolla SG, et al.  Hybrid PET/MR imaging for the prediction of left ventricular recovery after percutaneous revascularisation of coronary chronic total occlusions[J]. Eur J Nucl Med Mol Imaging, 2020, 47(13): 3074-3083.   doi: 10.1007/s00259-020-04877-w
[6] Priamo J, Adamopoulos D, Rager O, et al.  Downstream indication to revascularization following hybrid cardiac PET/MRI: preliminary results[J]. Nucl Med Commun, 2017, 38(6): 515-522.   doi: 10.1097/mnm.0000000000000680
[7] Beitzke D, Rasul S, Lassen ML, et al.  Assessment of myocardial viability in ischemic heart disease by PET/MRI: comparison of left ventricular perfusion, hibernation, and scar burden[J]. Acad Radiol, 2020, 27(2): 188-197.   doi: 10.1016/j.acra.2019.03.021
[8] Sun XX, Li SH, Wang YW, et al.  Rescue protocol to improve the image quality of 18F-FDG PET/CT myocardial metabolic imaging[J]. Clin Nucl Med, 2021, 46(5): 369-374.   doi: 10.1097/rlu.0000000000003572
[9] Wang L, Lu MJ, Feng L, et al.  Relationship of myocardial hibernation, scar, and angiographic collateral flow in ischemic cardiomyopathy with coronary chronic total occlusion[J]. J Nucl Cardiol, 2019, 26(5): 1720-1730.   doi: 10.1007/s12350-018-1241-8
[10] Roes SD, Kaandorp TA, Marsan NA, et al.  Agreement and disagreement between contrast-enhanced magnetic resonance imaging and nuclear imaging for assessment of myocardial viability[J]. Eur J Nucl Med Mol Imaging, 2009, 36(4): 594-601.   doi: 10.1007/s00259-008-1001-0
[11] Khalaf S, Chamsi-Pasha M, Al-Mallah MH.  Assessment of myocardial viability by PET[J]. Curr Opin Cardiol, 2019, 34(5): 466-472.   doi: 10.1097/hco.0000000000000652
[12] Klein C, Nekolla SG, Bengel FM, et al.  Assessment of myocardial viability with contrast-enhanced magnetic resonance imaging: comparison with positron emission tomography[J]. Circulation, 2002, 105(2): 162-167.   doi: 10.1161/hc0202.102123
[13] Kühl HP, Lipke CSA, Krombach GA, et al.  Assessment of reversible myocardial dysfunction in chronic ischaemic heart disease: comparison of contrast-enhanced cardiovascular magnetic resonance and a combined positron emission tomography-single photon emission computed tomography imaging protocol[J]. Eur Heart J, 2006, 27(7): 846-853.   doi: 10.1093/eurheartj/ehi747
[14]

Santos BS, Ferreira MJ. Positron emission tomography in ischemic heart disease[J/OL]. Rev Port Cardiol (Engl Ed), 2019, 38(8): 599−608 [2023-08-13]. https://pubmed.ncbi.nlm.nih.gov/31694787. DOI: 10.1016/j.repc.2019.02.011.
[15] Knuesel PR, Nanz D, Wyss C, et al.  Characterization of dysfunctional myocardium by positron emission tomography and magnetic resonance: relation to functional outcome after revascularization[J]. Circulation, 2003, 108(9): 1095-1100.   doi: 10.1161/01.Cir.0000085993.93936.Ba
[16] Kiko T, Yokokawa T, Misaka T, et al.  Myocardial viability with chronic total occlusion assessed by hybrid positron emission tomography/magnetic resonance imaging[J]. J Nucl Cardiol, 2021, 28(5): 2335-2342.   doi: 10.1007/s12350-020-02041-3
[17]

Kwon DH, Obuchowski NA, Marwick TH, et al. Jeopardized myocardium defined by late gadolinium enhancement magnetic resonance imaging predicts survival in patients with ischemic cardiomyopathy: impact of revascularization[J/OL]. J Am Heart Assoc, 2018, 7(22): e009394[2023-08-13]. https://www.ahajournals.org/doi/10.1161/JAHA.118.009394?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed. DOI: 10.1161/jaha.118.009394.
[18] Gerber BL, Rousseau MF, Ahn SA, et al.  Prognostic value of myocardial viability by delayed-enhanced magnetic resonance in patients with coronary artery disease and low ejection fraction: impact of revascularization therapy[J]. J Am Coll Cardiol, 2012, 59(9): 825-835.   doi: 10.1016/j.jacc.2011.09.073
[19] Bucciarelli-Ducci C, Auger D, Di Mario C, et al.  CMR guidance for recanalization of coronary chronic total occlusion[J]. JACC Cardiovasc Imaging, 2016, 9(5): 547-556.   doi: 10.1016/j.jcmg.2015.10.025
[20] Panza JA, Ellis AM, Al-Khalidi HR, et al.  Myocardial viability and long-term outcomes in ischemic cardiomyopathy[J]. N Engl J Med, 2019, 381(8): 739-748.   doi: 10.1056/NEJMoa1807365